Switzerland's Sandoz aims to double sales by 2035 in expanded biosimilars push

Positive

AI Analysis

Summary

Sandoz announced plans to double its sales by 2035 through an expanded biosimilars strategy. This represents a strategic growth initiative for the company's biosimilars business segment.

Financial Highlights

Guidance

double sales by 2035

Importance:3/10

Sentiment:

0.60

biosimilarsstrategygrowth guidanceSwitzerland

Related Companies

$SDZ

Read the original article

Published by Seeking Alpha Healthcare on September 8, 2026 9:38 AM

Read Original